Home – Page 59 – The Cancer Letter

Issue 10 - Mar 10, 2017

TCL43-10 (332 downloads)

DePinho resigns as MD Anderson president, acknowledges shortcomings as administrator
Ronald DePinho announced on March 8 that he will be stepping down as president of MD Anderson Cancer Center.
DePinho’s five-and-a-half years at the helm of the world’s largest cancer center were marked by unprecedented turbulence, questions of conflicts of interest, and unhappiness on the part of the faculty.
House Republicans publish legislation for replacing Obamacare with Trumpcare
The House Republicans on March 6 published the Obamacare repeal bill, touching off predictable tidal waves of recriminations, with Democrats stating that the bill would “rip healthcare away from millions of Americans, ration care for working families and seniors, and put insurance companies back in charge of healthcare decisions”
Note to international travelers: U.S. customs can take your laptop and ask for passwords
As spring meetings get going, many cancer organizations are offering what amounts to packing tips, suggesting that some electronic devices are best left at home.
In Brief
- Lynch steps in as CSO at Bristol-Myers Squibb
- Pharma companies collaborate in NCCN’s multi-industry project
- NCCN “Just Bag It!” campaign shoots for 100 new adopters by end of conference
- Targeted Anticancer Therapies Congress becomes an annual ESMO Event
- ASCO and ONS launch collaboration to advance engagement in CancerLinQ
- Siteman Cancer Center launches network with affiliation of Boone hospital
Drugs and Targets
- NICE recommends Vectibix for previously untreated metastatic colorectal cancer
- EnGeneIC receives Orphan designation for its technology in glioblastoma multiforme
- German Community of Gynecological Oncology acknowledges MammaPrint as having Level 1A clinical evidence

Issue 9 - Mar 3, 2017

TCL43-09 (1857 downloads)

Conversation with The Cancer Letter
Steve Hahn and his plan for rescuing MD Anderson
Steve Hahn didn’t apply for the job of Chief Operating Officer at MD Anderson Cancer Center. In fact, there was no COO job to apply to, and conversations that preceded the announcement of his new role took less than a week.
Medicare payment in January helps MD Anderson reduce its operating losses
MD Anderson Cancer Center reduced its year-to-date operating loss to $77.3 million in January, the fifth month of the fiscal year.
Cancer groups to Trump: FDA’s oncology division is NOT “slow and cumbersome”
FDA’s approval process for drugs is “slow and cumbersome,” President Donald Trump said in his first address to a joint session of Congress on Feb. 28.
In Brief
- Karmanos, Wayne State receive grant to conduct nation’s largest study of factors affecting African Americans with cancer
- Feldman named chief of breast surgery & surgical oncology, director of breast cancer services at Montefiore and Einstein
- Michael Rosen named chief communications officer at Pancreatic Cancer Action Network
- Open Science Prize goes to software tool for tracking viral outbreaks
- Fred Hutchinson announces Harold M. Weintraub Graduate Student Award winners
- Boehringer Ingelheim, Vanderbilt expand collaboration to tackle hard-to-treat cancers
- iKnowMed recognized as No. 1 oncology EHR by Black Book Research
- CTCA, Allscripts, NantHealth to launch clinical pathways, custom oncology treatment platform
- Blackfynn and CHOP expand partnership for data integration and analysis in pediatric brain tumors
Drugs and Targets
- FDA approves Xermelo as first and only treatment for carcinoid syndrome diarrhea
- FDA Accepts avelumab BLA for Priority Review for urothelial carcinoma
- BMS expands International Immuno-Oncology Network with addition of Columbia and MacCallum Cancer Centre
- Exelixis, BMS collaborate on late-stage combination trial in first-line RCC
- Exelixis, Roche to evaluate cabozantinib and atezolizumab in solid tumors
- Advaxis, SELLAS announce licensing agreement to develop antigen-targeting immunotherapy

Issue 8 - Feb 24, 2017

TCL43-08 (2737 downloads)

GAO: Power morcellation is a unique case study in patient harm
Hundreds died over two decades as reporting requirements were ignored.
FDA’s passive reliance on self-reporting by hospitals and device manufacturers allowed harm caused by power morcellators to go unnoticed for over two decades—likely contributing to injury and deaths of hundreds of women, according to the U.S. Government Accountability Office.
Conversation with The Cancer Letter
Marcia Crosse: This “failure of the adverse event reporting system” should serve as a “wake up call”
Hundreds of women were injured or have died from upstaging of unsuspected uterine cancer by power morcellation because FDA didn’t know the actual risk of cancer in fibroids, and hospitals failed to report harm, according to the U.S. Government Accountability Office.
Moonshot funds are not a substitute for sustained NCI funding, Lowy warns as prospect of year-long continuing resolution looms
Moonshot appropriations are not a substitute for sustained increases in appropriations, NCI Acting Director Doug Lowy said at the meeting of the National Cancer Advisory Board Feb. 15.
“It’s critically important for us to be able to continue to meet our obligations in terms of inflation, but far more important to meet our obligations to the cancer research community,” Lowy said at the virtual meeting.
In Brief
- Cleveland Clinic opens new cancer center
- Jeffrey Patrick new director of Ohio State Drug Development Institute
Drugs and Targets
- FDA approves Revlimid as maintenance in multiple myeloma following transplant
- Zykadia receives a Priority Review for frontline use in ALK+ metastatic NSCLC
- FDA accepts Mylan’s BLA for biosimilar pegfilgrastim
- MIODx licenses immunotherapy technologies from UCSF
Funding Opportunities
DOD Lung Cancer Research Program publishes anticipated funding opportunities
Due to the current Continuing Resolution, the Fiscal Year 2017 Defense Appropriations bill has not been passed.
Although funds have not been appropriated for the Department of Defense Lung Cancer Research Program (LCRP), the LCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY17 funding opportunities.

Page 59 of 115« First «...10 20 30 40 50...55 56 57 585960 61 62 63 64...70 80 90 100 110...»Last »

Hundreds died over two decades as reporting requirements were ignored.